|
Financial Information by Quarter (Unaudited) (Details) (USD $)
|
3 Months Ended | 12 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2013
|
Sep. 30, 2013
|
Jun. 30, 2013
|
Mar. 31, 2013
|
Dec. 31, 2012
|
Sep. 30, 2012
|
Jun. 30, 2012
|
Mar. 31, 2012
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2011
|
|
| Quarterly Financial Information [Abstract] | |||||||||||
| Research and development | $ 934,000 | $ 2,292,000 | $ 965,000 | $ 1,328,000 | $ 2,514,000 | $ 2,290,000 | $ 2,701,000 | $ 1,466,000 | $ 5,519,300 | $ 8,970,835 | $ 12,725,792 |
| Selling, general and administrative expense | 3,782,000 | 3,266,000 | 3,166,000 | 3,031,000 | 2,583,000 | 3,139,000 | 3,475,000 | 2,214,000 | 13,244,819 | 11,410,131 | 23,931,713 |
| Research and development expense | 2,819,000 | 4,261,000 | 3,131,000 | 3,645,000 | 4,396,000 | 4,170,000 | 5,183,000 | 4,465,000 | 13,856,500 | 18,213,036 | 18,367,348 |
| Patent preparation fees | 333,000 | 329,000 | 301,000 | 458,000 | 794,000 | 377,000 | 376,000 | 336,000 | 1,421,218 | 1,883,405 | 1,808,168 |
| Restructuring charges | 513,000 | 0 | 0 | 0 | 512,944 | 0 | 0 | ||||
| Operating loss | (6,513,000) | (5,564,000) | (5,633,000) | (5,807,000) | (5,259,000) | (5,396,000) | (6,332,000) | (5,549,000) | (23,516,181) | (22,535,737) | (31,381,437) |
| Net income (loss) | $ (4,338,000) | $ (4,902,000) | $ (3,061,000) | $ (4,876,000) | $ (2,618,000) | $ (3,059,000) | $ (3,767,000) | $ (4,616,000) | $ (17,177,333) | $ (14,059,539) | $ 29,099,579 |
| Earning (loss) per share: basic and diluted | $ (0.08) | $ (0.09) | $ (0.06) | $ (0.09) | $ (0.04) | $ (0.06) | $ (0.07) | $ (0.09) | |||